Avanos Medical, Inc. AVNS
We take great care to ensure that the data presented and summarized in this overview for AVANOS MEDICAL, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVNS
View all-
Black Rock Inc. New York, NY7.01MShares$113 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$85.6 Million0.0% of portfolio
-
Rgm Capital, LLC Naples, FL3.17MShares$51 Million3.28% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.59MShares$41.6 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.37MShares$38.1 Million0.03% of portfolio
-
Westwood Holdings Group Inc Dallas, TX1.99MShares$32 Million0.38% of portfolio
-
State Street Corp Boston, MA1.82MShares$29.3 Million0.0% of portfolio
-
Brown Advisory Inc1.7MShares$27.4 Million0.05% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.38MShares$22.2 Million0.08% of portfolio
-
Paradice Investment Management LLC1.26MShares$20.3 Million5.37% of portfolio
Latest Institutional Activity in AVNS
Top Purchases
Top Sells
About AVNS
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Insider Transactions at AVNS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 03
2024
|
Michael Greiner Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+4.74%
|
-
|
Oct 29
2024
|
Michael Greiner Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,189
+18.8%
|
-
|
Sep 05
2024
|
John Joseph Hurley Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,001
+23.73%
|
-
|
Jul 22
2024
|
Mojirade James SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-0.96%
|
$14,364
$21.99 P/Share
|
Mar 18
2024
|
Kerr Holbrook SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,596
-2.02%
|
$68,324
$19.09 P/Share
|
Mar 18
2024
|
Kerr Holbrook SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,531
+2.74%
|
-
|
Mar 18
2024
|
Michael Greiner Interim CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,005
-2.92%
|
$171,095
$19.09 P/Share
|
Mar 18
2024
|
Michael Greiner Interim CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,219
+2.64%
|
-
|
Mar 18
2024
|
Joseph Fralin Woody Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,765
-3.77%
|
$641,535
$19.09 P/Share
|
Mar 18
2024
|
Joseph Fralin Woody Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,821
+3.37%
|
-
|
Mar 14
2024
|
Michael Greiner Interim CEO |
SELL
Open market or private sale
|
Direct |
8,000
-0.85%
|
$152,000
$19.14 P/Share
|
Mar 11
2024
|
Julie Ann Shimer Director |
BUY
Open market or private purchase
|
Direct |
500
+0.99%
|
$9,500
$19.85 P/Share
|
Mar 06
2024
|
Kerr Holbrook SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,618
-2.91%
|
$49,742
$19.0 P/Share
|
Mar 06
2024
|
Kerr Holbrook SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,573
+28.94%
|
$694,887
$19.14 P/Share
|
Mar 06
2024
|
Michael Greiner Interim CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,118
-3.11%
|
$97,242
$19.0 P/Share
|
Mar 06
2024
|
Michael Greiner Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
57,471
+25.88%
|
$1,091,949
$19.14 P/Share
|
Mar 06
2024
|
Sudhakar Varshney SVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
1,394
-4.41%
|
$26,486
$19.0 P/Share
|
Mar 06
2024
|
Mojirade James SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,951
-2.67%
|
$37,069
$19.0 P/Share
|
Mar 06
2024
|
Mojirade James SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,695
+29.62%
|
$583,205
$19.14 P/Share
|
Mar 06
2024
|
John Joseph Hurley Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-2.08%
|
$2,679
$19.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 363K shares |
---|---|
Open market or private purchase | 500 shares |
Exercise of conversion of derivative security | 22.6K shares |
Payment of exercise price or tax liability | 84.3K shares |
---|---|
Open market or private sale | 8K shares |